EUVIMEDEUVIMED entdecken
Open Access

Plasma vitronectin is reduced in patients with myasthenia gravis: Diagnostic and pathophysiological potential

Antonio Junior Lepedda iD, Giovanni Andrea Deiana, Omar Lobina, Gabriele Nieddu, Paola Baldinu, Pierina De Muro, Francesca Andreetta, Elia Sechi, Giannina Arru, Davide Giacomo Corda, Gian Pietro Sechi, Marilena Formato

Journal of Circulating Biomarkers · 2019

DOI: 10.1177/1849454419875912 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Circulating Biomarkers, 2019. Verfasst von Antonio Junior Lepedda und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, University of Sassari, Viale San Pietro, Sassari, Italy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myasthenia gravis (MG) is an autoimmune disease leading to varying degrees of skeletal muscle weakness. It is caused by specific antibodies directed against definite components in the postsynaptic membrane at the neuromuscular junction (NMJ), such as the acetylcholine receptor (AChR) and the muscle-specific kinase (MUSK) receptor. In clinical practice, MG patients may be classified into three main subgroups based on the occurrence of serum autoantibodies directed against AChR or MUSK receptor or antibody-negative. As the MG subgroups differ in terms of clinical characteristics, disease pathogenesis, prognosis, and response to therapies, they could benefit from targeted treatment as well as the detection of other possible disease biomarkers. We performed proteomics on plasma fractions enriched in low-abundance proteins to identify potential biomarkers according to different autoimmune responses. By this approach, we evidenced a significant reduction of vitronectin in MG patients compared to healthy controls, irrespective of the autoantibodies NMJ target. The obtained results were validated by mono- and two-dimensional Western blotting analysis. Vitronectin is a multifunctional glycoprotein involved in the regulation of several pathophysiological processes, including complement-dependent immune response, coagulation, fibrinolysis, pericellular proteolysis, cell attachment, and spreading. The pathophysiological significance of the reduction of plasma vitronectin in MG patients has yet to be fully elucidated. It could be related either to a possible deposition of vitronectin at NMJ to counteract the complement-mediated muscle damage at this level or to a parallel variation of this glycoprotein in the muscle extracellular matrix with secondary induced alteration in clustering of AChRs at NMJ, as it occurs with variation in concentrations of agrin, another extracellular matrix component. The clinical value of measuring plasma vitronectin has yet to be defined. According to present findings, significantly lower plasma values of this glycoprotein might be indicative of an impaired complement-dependent immune response.

Schlagwörter

Stichwörter der Autor:innen

Myasthenia gravisautoimmunitybiomarkersproteomicsvitronectin

Autor:innen und Institutionen

  • Department of Biomedical Sciences, University of Sassari, Viale San Pietro, Sassari, Italy.
  • Department of Medical, Surgical and Experimental Sciences, University of Sassari, Viale San Pietro, Sassari, Italy.
  • Diagnostic Laboratory of Neuroimmunolgy, U.O. Neurologia IV, I.R.C.C.S. Fondazione Istituto Neurologico "C. Besta", Milano, Italy.

ORCID-Profile: Antonio Junior Lepedda

Zitieren

APA

Lepedda, A. J., Deiana, G. A., Lobina, O., Nieddu, G., Baldinu, P., De Muro, P., Andreetta, F., Sechi, E., Arru, G., Corda, D. G., Sechi, G. P., & Formato, M. (2019). Plasma vitronectin is reduced in patients with myasthenia gravis: Diagnostic and pathophysiological potential. Journal of Circulating Biomarkers. https://doi.org/10.1177/1849454419875912

Vancouver

Lepedda AJ, Deiana GA, Lobina O, Nieddu G, Baldinu P, De Muro P, et al. Plasma vitronectin is reduced in patients with myasthenia gravis: Diagnostic and pathophysiological potential. Journal of Circulating Biomarkers. 2019. doi:10.1177/1849454419875912

BibTeX
@article{Lepedda2019,
  author = {Lepedda, Antonio Junior and Deiana, Giovanni Andrea and Lobina, Omar and Nieddu, Gabriele and Baldinu, Paola and De Muro, Pierina and Andreetta, Francesca and Sechi, Elia and Arru, Giannina and Corda, Davide Giacomo and Sechi, Gian Pietro and Formato, Marilena},
  title = {Plasma vitronectin is reduced in patients with myasthenia gravis: Diagnostic and pathophysiological potential},
  journal = {Journal of Circulating Biomarkers},
  year = {2019},
  doi = {10.1177/1849454419875912}
}
Kostenlos starten →